-+ 0.00%
-+ 0.00%
-+ 0.00%

Gilead Agrees to Buy PepStar’s IL-23R Inhibitor Program for $1.28 Billion Upfront

PUBT·10/22/2026 20:13:41
Listen to the news
Gilead Agrees to Buy PepStar’s IL-23R Inhibitor Program for $1.28 Billion Upfront
  • Gilead Sciences agreed to acquire PepStar Therapeutics’ oral IL-23R inhibitor program for $1.28 billion in upfront cash, payable at closing.
  • The deal includes worldwide rights to lead asset HCXT-2001, a clinical-stage oral treatment with potential applications in inflammatory bowel disease.
  • Closing is expected in the fourth quarter of 2026, subject to customary conditions.
  • The transaction is expected to reduce GAAP and non-GAAP earnings per share by approximately $0.79 to $0.83 in the quarter.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610221605BIZWIRE_USPR_____20261022_BW181871) on October 22, 2026, and is solely responsible for the information contained therein.